We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+17.73%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$717M
AUM Growth
+$143M
Cap. Flow
+$179M
Cap. Flow %
24.96%
Top 10 Hldgs %
42.64%
Holding
176
New
63
Increased
14
Reduced
29
Closed
31

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$15.9M
2
RCUS icon
Arcus Biosciences
RCUS
+$9.44M
3
AVTX icon
Avalo Therapeutics
AVTX
+$9.44M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$9.12M
5
BPMC
Blueprint Medicines
BPMC
+$8.44M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$20.7M
2
SLNO
Soleno Therapeutics
SLNO
+$10.7M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$8.35M
4
NUVL
Nuvalent
NUVL
+$8.24M
5
AMGN icon
Amgen
AMGN
+$8.18M

Sector Composition

Rank Sector Weight
1 Healthcare 44.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.2B
$49.4M 6.89%
+500,000
New +$49.1M
AMGN icon
2
CALL
Amgen
AMGN
$203B
$47M 6.56%
146,000
+145,400
+24,233% +$47.6M
VRTX icon
3
CALL
Vertex Pharmaceuticals
VRTX
$122B
$46.5M 6.49%
+100,000
New +$48M
VRTX icon
4
PUT
Vertex Pharmaceuticals
VRTX
$122B
$46.5M 6.49%
+100,000
New +$48M
TARS icon
5
Tarsus Pharmaceuticals
TARS
$2.53B
$33.9M 4.73%
1,030,277
+230,000
+29% +$6.46M
CRNX icon
6
Crinetics Pharmaceuticals
CRNX
$8.87B
$21.8M 3.04%
426,913
-161,905
-27% -$8.35M
JANX icon
7
PUT
Janux Therapeutics
JANX
$938M
$16.6M 2.31%
+365,200
New +$15.9M
BHVN icon
8
PUT
Biohaven
BHVN
$2.13B
$16.3M 2.27%
+325,600
New +$12.7M
IMVT icon
9
CALL
Immunovant
IMVT
$8.01B
$14.3M 1.99%
500,000
+499,000
+49,900% +$14.7M
ANAB icon
10
PUT
AnaptysBio
ANAB
$1.6B
$13.5M 1.89%
+404,300
New +$13.8M
ELVN icon
11
Enliven Therapeutics
ELVN
$3.78B
$12.8M 1.78%
499,566
-86,986
-15% -$2.01M
ANAB icon
12
CALL
AnaptysBio
ANAB
$1.6B
$11.7M 1.63%
+350,000
New +$12M
RCUS icon
13
Arcus Biosciences
RCUS
$3.61B
$11.4M 1.59%
744,000
+599,000
+413% +$9.44M
VRDN icon
14
Viridian Therapeutics
VRDN
$2.12B
$11.4M 1.59%
+499,977
New +$8.17M
INSM icon
15
Insmed
INSM
$23.1B
$11.3M 1.58%
154,835
+107,000
+224% +$7.9M
SLNO
16
DELISTED
Soleno Therapeutics
SLNO
$11.2M 1.56%
221,437
-224,014
-50% -$10.7M
CLDX icon
17
CALL
Celldex Therapeutics
CLDX
$2.75B
$10.4M 1.45%
+305,500
New +$11.6M
CLDX icon
18
PUT
Celldex Therapeutics
CLDX
$2.75B
$10.4M 1.45%
+305,500
New +$11.6M
RARE icon
19
Ultragenyx Pharmaceutical
RARE
$2.64B
$9.94M 1.39%
+179,000
New +$9.12M
AVTX icon
20
Avalo Therapeutics
AVTX
$956M
$9.22M 1.29%
970,359
+915,629
+1,673% +$9.44M
CYTK icon
21
Cytokinetics
CYTK
$11B
$8.98M 1.25%
170,147
– –
SYRE icon
22
Spyre Therapeutics
SYRE
$8.82B
$8.89M 1.24%
+302,247
New +$8.42M
CPRX
23
DELISTED
Catalyst Pharmaceutical
CPRX
$8.31M 1.16%
417,850
-100,536
-19% -$1.86M
TECX
24
Tectonic Therapeutic
TECX
$575M
$8.09M 1.13%
267,145
+204,309
+325% +$3.73M
BPMC
25
DELISTED
Blueprint Medicines
BPMC
$7.86M 1.1%
+85,000
New +$8.44M
1
2 3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Ikarian Capital held 176 positions worth $717M, up 25% from $574M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Ikarian Capital deployed $179M of net new capital in Q3 2024, opening 63 new positions and adding to 14 existing holdings. Its largest new stake was BeOne Medicines Ltd: 88,167 shares worth $1.64M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 56% a quarter earlier.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $20.7M trimmed.

  • Ikarian Capital's largest Q3 2024 buy was BeOne Medicines Ltd: 88,167 shares worth $1.64M.
  • Ikarian Capital added most to Arcus Biosciences in Q3 2024, an estimated $9.44M increase.
  • Ikarian Capital's biggest Q3 2024 reduction was Sarepta Therapeutics, cutting an estimated $20.7M.
  • Ikarian Capital fully exited Immunovant in Q3 2024, selling an estimated $8.17M.
  • Ikarian Capital's ten largest holdings make up 43% of its $717M portfolio in Q3 2024.
  • Ikarian Capital opened 63 new positions and closed 31 in Q3 2024.
  • Ikarian Capital's portfolio value rose 25% quarter-over-quarter to $717M.

Based on Ikarian Capital's 13F filing for Q3 2024, filed 14 Nov 2024.